BURLINGTON, Mass. — 908 Devices Inc. has appointed Kola Otitoju as its Chief Business & Strategy Officer, a newly created role aimed at accelerating the company’s growth and strategic expansion across public health, safety, and defense technology markets.
In the position, Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as the company seeks to expand its market presence.
Otitoju brings more than 25 years of executive leadership experience spanning medical technology, life sciences, and industrial sectors. Most recently, he served as Senior Vice President of Strategy & Business Development at Repligen Corporation, where he led global corporate strategy and executed more than 15 mergers, acquisitions, and strategic partnerships over six years. During that time, the company achieved approximately 20 percent compound annual growth, surpassing $700 million in revenue.
“We are thrilled to welcome Kola to 908 Devices as we build on the momentum of our 2.0 transformation and enter our next phase of growth,” said Kevin J. Knopp, CEO and Co-founder. “His exceptional track record in driving both organic and inorganic growth makes him the ideal leader to accelerate our strategic initiatives and deliver long-term shareholder value. M&A and industry partnerships have already been successful and integral to our strategy, and we intend to lean in further. Kola’s appointment reinforces this commitment and positions us to execute at an even higher level.”
Prior to his role at Repligen, Otitoju held senior strategy and business development positions at Candela Medical, Baxter International, and GE Healthcare, where he served as Managing Director and Head of Business Development. Earlier in his career, he spent eight years in investment banking at Credit Suisse and Bank of America Securities, advising on transactions across healthcare, industrial, and technology sectors. He holds an MBA from Harvard Business School, a master’s degree in electrical engineering from Cornell University, and a bachelor’s degree in information systems from Imperial College London.
The company also announced an inducement equity grant tied to Otitoju’s hiring. On April 21, 2026, the Compensation Committee awarded him 110,193 restricted stock units and stock options to purchase 146,789 shares of common stock under the company’s 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units will vest in equal portions over three years on May 1, 2027, May 1, 2028, and May 1, 2029, contingent on continued employment. The stock options carry an exercise price of $7.26 per share, matching the company’s closing stock price on the grant date, and will vest over three years, with one-third vesting on May 1, 2027, and the remainder vesting in monthly installments over the following two years.
